Adverse events and technical complaints related to central venous catheters marketed in Brazil

Abstract

BackgroundSerum lactate dehydrogenase is a non-specific marker for lymphoma whose prognostic significance is well established for both indolent and aggressive lymphomas at the time of diagnosis. The performance characteristics of this enzyme in predicting relapse in patients with diffuse large B-cell lymphoma has not been well studied. MethodsThis study compared serum lactate dehydrogenase levels in 27 patients with diffuse large B-cell lymphoma who relapsed after sustaining a complete response versus 87 patients who did not relapse. For relapsed patients, the serum lactate dehydrogenase level at relapse was compared with the level three months before (considered baseline). For non-relapsed patients, the last two levels during follow-up were compared. For statistical analysis the T-test was used to compare differences in mean values between groups. The sensitivity, specificity, positive and negative predictive values for serum lactate dehydrogenase in detecting relapse compared to confirmatory imaging were calculated. ResultsAt relapse, only 33% patients had increases in serum lactate dehydrogenase above the upper limit of normal. The mean increase was 1.2-fold above the upper limit of normal for relapsed vs. 0.83 for those who did not relapse (p-value = 0.59). The mean increase in serum lactate dehydrogenase, from baseline, was 1.1-fold in non-relapsed vs. 1.3 in relapsed patients (p-value = 0.3). The likelihood ratio of relapse was 4.65 for patients who had 1.5-fold increases in serum lactate dehydrogenase above baseline (p-value = 0.03). The sensitivity, specificity, positive and negative predictive values of 1.5-fold increases for detecting relapse, compared to clinical and imaging findings were 0.18, 0.95, 0.55, and 0.79, respectively. ConclusionA 1.5-fold increase in serum lactate dehydrogenase, over a period of 3 months, is associated with increased likelihood of relapse from diffuse large B-cell lymphoma.

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA

“…3A and fig. S9A) (50). Notably, whereas 100% of pretreatment samples had detectable ctDNA, only 37% of samples had abnormally high LDH, demonstrating superior sensitivity of ctDNA.…”

Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma – MCT1 as potential target in diffuse large B cell lymphoma

“…LDH, an enzyme that catalyses the conversion of pyruvate to lactate under hypoxia and/or as a result of oncogenic mutations, ensures an efficient glycolytic metabolism and a reduced dependency on oxygen [73]. Serum LDH is used as a biomarker for various neoplasms [74], including haematological malignancies [75,76]. Its increase may reflect an increase in tumour mass, tumour kinetics with a high mitotic index and a high rate of cell death.…”

Prognostic and Clinicopathological Value of Survivin in Diffuse Large B-cell Lymphoma

“…Besides, it has been widely acknowledged that elevated LDH is associated with increased likelihood of relapse in DLBCL patients. 41 Survivin apparent high expression in relapsed patients sheds light on the potential effectiveness of survivin suppressors targeting relapsed DLBCL patients. As for the indicator of patients’ therapeutic response, CR presented direct relationship with survivin expression (OR: 0.478, 95% CI: 0.345–0.662, P < 0.001).…”